EUVIMEDEUVIMED entdecken
Crossref

STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )

Roshni Bibi iD, Melvin George, Koustav Sarkar iD

Immunology · 2026

DOI: 10.1111/imm.70121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Roshni Bibi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immunology and Gene Technology Lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankula…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Epigenesis, Genetic, STAT2 Transcription Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Indian Council of Medical Research, Ministry of Tribal Affairs, Govt. of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐small cell lung cancer (NSCLC) is an aggressive malignancy necessitating innovative therapeutic approaches to augment antitumour immunity. Our study examined the function of the STAT2 protein in CD4 + T helper cells, which are essential for the immune response to cancer. We utilised CRISPR/Cas9 to ablate STAT2 in CD4 + T cells from stage I NSCLC patients ( n = 30), assessing its impact on cellular function and diverse epigenetic pathways. Our findings indicate that the depletion of STAT2 markedly enhances the anti‐cancer efficacy of T lymphocytes. Deletion of STAT2 diminished oxidative stress, enhanced the synthesis of advantageous TH1 cytokines. STAT2 depletion reduced DNA methylation and R‐loop formation. T cells deficient in STAT2 showed enhanced efficacy in activating cytotoxic T lymphocytes to eliminate cancer cells. These findings identify STAT2 as a crucial regulator of immune function in the lung cancer microenvironment. Targeted STAT2 inhibition in tumour‐reactive T cells may reinstate anti‐tumour immunity, although systemic inhibition requires further research on targeted intervention strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsEpigenesis, GeneticSTAT2 Transcription FactorT-Lymphocytes, Helper-InducerHumansCell DifferentiationDNA MethylationEpitranscriptomeTumor MicroenvironmentGene Expression Regulation, NeoplasticAnimals

Stichwörter der Autor:innen

CD4+ T helper cellsCRISPR/Cas9 knock outDNA methylationRNA–DNA hybrid immunoprecipitation (RDIP)STAT2m6A RNA methylation

Substanzen

STAT2 Transcription FactorSTAT2 protein, human

Autor:innen und Institutionen

  • Cancer Immunology and Gene Technology Lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
  • Department Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu, India.

ORCID-Profile: Roshni Bibi, Koustav Sarkar

Förderung

  • Indian Council of Medical Research
  • Ministry of Tribal Affairs, Govt. of India

Zitieren

APA

Bibi, R., George, M., & Sarkar, K. (2026). STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC ). Immunology. https://doi.org/10.1111/imm.70121

Vancouver

Bibi R, George M, Sarkar K. STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC ). Immunology. 2026. doi:10.1111/imm.70121

BibTeX
@article{Bibi2026,
  author = {Bibi, Roshni and George, Melvin and Sarkar, Koustav},
  title = {STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )},
  journal = {Immunology},
  year = {2026},
  doi = {10.1111/imm.70121}
}
Kostenlos starten →